Pharmaceutical Executive
August 01, 2006
Features
0
0
Think you've been around a long time? When's the last time your company gave a doctor a cigarette lighter with your logo on it? Put any corks in medicine bottles lately? Can you remember the last hero shot of a pharma CEO on the cover of Time? We can. And we have the artifacts to prove it...
August 01, 2006
Column
0
0
Do you remember where you were when Mevacor was approved? OK, what was on the radio at the time?
August 01, 2006
Features
0
0
Is the golden age of drug development over? Fat chance. Decade-by-decade comparisons show how new medicines improve on old ones. And that's innovation.
August 01, 2006
0
0
Pharma restrictions of sales tactics vary from state to state, creating new compliance challenges.
August 01, 2006
From the Editor
0
0
The road forward for both public health and the industry is going to require more trust and intimacy, not less, between patients, physicians, FDA, and pharma. Patients need to see a fully functioning set of checks and balances-not what they're seeing today.
August 01, 2006
0
0
Pharma leaders (and Pharm Exec readers) reflect on the ideas and events that revolutionized the industry over the last quarter of a century--and what to watch for in the next 25.
August 01, 2006
0
0
See how well you did on Pharmaceutical Executive's 25th anniversary quiz.
August 01, 2006
Features
0
0
In 1981, when Pharm Exec published its first issue, the pharmaceutical world was a very different place: There was no direct-to-consumer advertising, no map of the genome, no high-speed screening of millions of compounds. The process of marketing and selling drugs was discreet and nearly invisible to the public; and sales forces, by today's standards, were minuscule. The first biotechs had just launched; and the Bayh-Dole Act, passed the year before, had begun to lay the groundwork for the explosion of research-driven university spin-off companies that transformed the face of research in the 1990s.
August 01, 2006
Features
0
0
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.